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Determining Mechanisms of Response to Polo-like Kinase 1 Inhibition in Non-Small Cell Lung
Cancer
Ruchitha Goonatilake, B.S.
Supervisory Professor: Faye M. Johnson, M.D., Ph.D.

Non-small c ell l ung c ancer ( NSCLC) i s the l eading c ause o f c ancer-related deat h
worldwide. The discovery of genetic alterations in some patients (~15%) has made it possible to
use targeted therapies without the use of chemotherapy. To identify potential therapeutic targets
in NSCLC, we systematically evaluated two cancer cell line databases with sensitivity data for a
broad range of drugs. We identified polo-like kinase 1 (Plk1) as the most promising target for
further i nvestigation ba sed on a s ubset o f s ensitive c ell l ines and i nhibitors t hat w ere i n
advanced clinical development.
To identify potential biomarkers of response and mechanisms of Plk1 inhibitorinduced apoptosis, we performed an i ntegrated analysis of gene and pr otein expression, gene
mutation, and dr ug sensitivity using three Plk1 inhibitors (volasertib, BI2536, GSK461364) in a
large panel o f N SCLC c ell l ines.

We obs erved t hat t he N SCLC c ell l ines ha ve v arying

sensitivities t o P lk1 in hibition, w ith a s maller subset de monstrating s ensitivity t o al l t hree
inhibitors. Plk1 inhibition led to increase of cells with 4N DNA content, but only sensitive cell
lines underwent substantial apoptosis following Plk1 inhibition. NSCLC lines with a high
epithelial-mesenchymal t ransition gene signature s core (i.e., mesenchymal l ines) w ere m ore
sensitive to Plk1 inhibitors than epithelial lines (p<0.02).

Similarly, proteomic profiling

demonstrated that E-cadherin expression was higher in the resistant cell lines (p<0.01).
Induction o f an epi thelial phenot ype us ing miR-200 ex pression i ncreased r esistance t o P lk1
inhibition, w hereas ex pression o f ZE B1 i ncreased s ensitivity t o P lk1 i nhibition. A dditionally,
treatment o f with TGF-β to induce EMT sensitized a resistant cell line and led to increased
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apoptosis a fter P lk1 i nhibition, c ompared t o par ental c ells. KRAS mutation and a lterations i n
tight-junction, ErbB, and Rho signaling pathways also correlated with drug response.
We dem onstrate t hat epi thelial-mesenchymal t ransition l eads to P lk1 i nhibitor
sensitivity in a la rge-scale, i ntegrated anal ysis o f P lk1 i nhibitor sensitivity. O ur findings hav e
important clinical implications for mesenchymal NSCLC, as a s ignificant subset of this disease
associated with resistance to currently approved targeted therapies.
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Lung Cancer
Lung cancer is the deadliest cause of cancer in the world, with estimates
approximating more than 200,000 deaths in the United States alone for 2015 (1). Lung
cancer is usually split into two main categories: non-small cell lung cancer (NSCLC) and
small cell lung cancer (SCLC). NSCLC makes up approximately 85% of all lung cancer
cases whereas SCLC makes up 15% (1) Most of the lung cancer cases are attributed to
tobacco use. However, there are a host of other factors which may contribute, including
environmental causes, such as exposure to secondhand smoke, air pollution, inherited
factors, , and other substances (2-4). Lung cancer is not frequently found in people
under 35, and the incidence of lung cancer rises exponentially afterwards (5). Although
there have been great advances in terms of early detection and treatment, most new
cases are usually found at late stages and are resistant to therapy (6). The five-year
survival rate for all stages of lung cancer is 54% for localized disease, but decreases to
4% in cases of distant metastasis (1, 7).
Non-small cell lung cancer
NSCLC is made up of three major histologies: squamous cell carcinoma (SCC),
large cell carcinoma, and adenocarcinoma. There are several other histologies which
occur much less frequently. Adenocarcinoma accounts for approximately 50% of
NSCLC, and usually originates in the more peripheral regions of the lungs (8). Although
adenocarcinoma is associated with tobacco use, it is more common in the non-smoking
population than other subtypes (9). Another major histology of NSCLC is the squamous
cell carcinoma which originates from the proximal airway. SCC accounts for
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approximately 35% of NSCLC, and 11% are accounted for by large cell carcinoma,
originating from the bronchi located more towards the center of the lungs (8).
Common genetic aberrations in NSCLC
The development of tumors is not a single step process; on the contrary, it is a
complex process which occurs due to the accumulation of several genetic alterations
over a period of time (10). These accumulating alterations allow for cancer cells to have
advantages in growth and survival compared to normal cells. Genetic aberrations have
been characterized in NSCLC which contribute to various advantages in proliferation,
survival, migration, invasion, and resistance to programmed cell death - all hallmarks of
cancer (11). The most frequent aberrations in adenocarcinoma include mutations in
Kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor
(EGFR), met proto-oncogene (MET), LKB1 (serine/threonine kinase 11), and TP53 (12).
EGFR gene amplification is seen in around 15% of patients while MET amplification is
seen in approximately 20% of adenocarcinoma patients (12). In the squamous cell
carcinoma, mutations which frequently occur also include MET, TP53, LKB1, and
KRAS. EGFR and MET amplification are seen in 30% and 21% of SCCs and EGFR
mutations are rare (12). Other aberrations which have been found in NSCLC at lower
frequencies include BRAF mutations, HER2 mutations, TITF-1 amplification, and ALK
translocations (13).

Treatment of NSCLC
Patients diagnosed with early stages of disease usually undergo surgery and
adjuvant chemotherapy may allow for more beneficial results with resected tumors (4).
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Patients with locally advanced disease are treated with chemotherapy and radiation in
conjunction, either with or without surgery (14). Patients with metastatic disease are
usually treated with palliative chemotherapy (14). Chemotherapy usually is made up of
platinum based compounds which are combined with other cytotoxic agents such as
taxanes or pemetrexed (8).
Treatments targeting a specific oncogenic driver molecule based on genetic
alterations have recently been developed for NSCLC. An example of these targeted
therapies are the EGFR tyrosine kinase inhibitors, which have resulted in significant
improvements in response rates and progression-free survival for subsets of patients
with these genetic alterations (15). Another example is the development of anaplastic
lymphoma kinase (ALK) inhibitors for NSCLC patients with EML4-ALK translocations.
ALK and EGFR inhibitors are currently approved for use in NSCLC patients with
metastatic cancer (16). Despite these promising results, some patients do not respond
to the inhibitors and nearly all who initially respond develop resistance (15).
Hallmarks of cancer
Cancer development is a complex process in which cancer cells must overcome
many obstacles to thrive. Their genomes are changed at several stages through
mutations, amplification, deletion and other mechanisms. Douglas Hanahan and Robert
Weinberg proposed that the diversity of cancer genotypes is a result of eight essential
physiological alterations: evading apoptosis, self-sufficiency in growth signals,
insensitivity to anti-growth signals, sustained angiogenesis, limitless replicative
potential, tissue invasion & metastasis, abnormal metabolic pathways, and evading the
immune system (10). These hallmarks are novel capabilities that cells acquire during
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tumorigenesis, that enable them to overcome anticancer mechanisms which have been
programmed into cells.
In addition to breaking through the physiological barriers through acquisition of
these hallmarks, cancer is viewed as a disease of the cell cycle (17). This is due to the
fact that cells undergo disruptions which can affect the cell cycle machinery which leads
to the increased or inappropriate proliferation, a major hallmark of cancer. These
defects can target the cell cycle itself or upstream signaling which has consequences in
the cell cycle.
Phases of the cell cycle
The eukaryotic process of cell division known as mitosis has been well studied
(18). Eukaryotic cells follow a program to divide and proliferate called the cell cycle; this
process can be divided into three phases: interphase, mitotic (M) phase, and
cytokinesis. In interphase, the cell grows, duplicates its DNA content, and obtains the
necessary nutrients for the ensuing division. In the M phase, the cell divides into two
daughter cells. This process is finalized in the cytokinesis. To make sure cells divide
correctly, there are control mechanisms termed the cell cycle checkpoints.
Nonproliferating cells are thought to be in the G0 phase. Here, the cells are able
to remain quiescent for a long interval of time. Senescent cells enter this phase
permanently in response to DNA damage or degradation (19). Interphase of the cell
cycle consists of three subphases, Gap 1 (G1), S, and Gap 2 (G2). Interphase consists
of about 90% of the total time necessary for the cell cycle process (20). The G1 phase
is the interval between the M phase of the previous cycle to S phase of the subsequent
cycle. Here, the cells need to acquire the necessary nutrients to be able to sustain
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themselves during the cell cycle. The ensuing S phase begins as the DNA replication
starts; it is completed once all the chromosomes have replicated resulting in two sister
chromatids. After the S phase is properly completed, the G2 phase of interphase
occurs. The G2 phase is often characterized by quick cell growth and the synthesis of
various proteins essential for cell division (21).
After the G2 phase, the relatively short M phase begins. In the M phase, the cell
separates its chromosomes into two separate nuclei. Chromosomes condense and are
pulled apart by cellular machinery to opposite parts of the cell. The nuclear envelope
forms around the chromosomes, and begins forming the two identical daughter cells.
The M phase consists of four stages: prophase, prometaphase/metaphase, anaphase,
and telophase. Prophase is the beginning of mitosis, where the nuclear envelope
breaks down, and condensed chromosomes start to appear, consisting of two sister
chromatids which have been produced during the S phase. Additionally, the duplicated
centrosomes move towards the opposite sides of the nucleus and will be the two poles
of the mitotic spindle. In prometaphase the microtubules of the spindle attach to the
kinetochores of the chromosomes. The kinetochores of the sister chromatids are
located on both sides of each chromosome, so the microtubules from the two sides of
the spindle will be able to attach. During metaphase the condensed chromosomes then
align at the equatorial plate of the dividing cell known as the metaphase plate. In
anaphase the sister chromatids break apart and move towards the opposite sides of the
mitotic spindle. The last step is telophase, where the nuclei form again and the
chromosomes decondense. The process is then followed by cytokinesis, a process in
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which the nuclei, organelles and other features are equally distributed to the two
identical daughter cells which will be in interphase (21).
Many checkpoints exist so that damaged or incomplete DNA is not taken up by
the daughter cells. The main checkpoints that exist in the cell cycle are the G1/S, G2/M,
and M checkpoints. The G1/S checkpoint is the rate-limiting and most important step in
the cell cycle; it is known as the restriction point (21). The stages of the cell cycle are
regulated by several proteins discussed in the next section.
Cyclins, CDKs, and Mitotic Entry
Two kinds of regulatory proteins are in charge of the cell’s progress in the cell
cycle: these are the cyclins and the cyclin-dependent kinases (CDKs). Together the two
components form heterodimers where the cyclins are the regulatory subunit and the
CDK is the catalytic subunit (17). Cyclins do not have catalytic activity on their own,
whereas CDKs are inactive without the cyclin subunit. When the cyclin binds to the
CDK, they phosphorylate downstream signaling and either activate or inactivate
downstream targets to control the progression to different phases of the cycle.
Eukaryotic cells have nine CDKs, of which five have direct involvement in the cell
cycle(17). In mammals, CDK1 and its binding cyclin partners A2 and B are enough to
drive the cell cycle. Cyclin-CDK complexes involved in earlier cell-cycle phases are
needed to activate complexes in later phases. Each phase of the cell cycle is governed
by the complexes of different cyclins and CDKs as shown in Table 1.
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Phase Cyclin CDK
G0

C

CDK3

G1

D, E

CDK4, CDK2, CDK6

S

A, E

CDK2

G2

A

CDK2, CDK1

M

B

CDK1

Table 1. Cyclin-CDK complexes involved in the phases of the cell cycle.

The entry into mitosis is regulated by the CDK1-cyclin B complex (22). Normal
cells usually have low cyclin B expression when the S phase begins and the levels
increase at the end of G2. Cyclin B levels are regulated by several transcription factors,
including p53, p21, and c-Myc. These transcription factors allow for the accumulation of
CDK1-cyclin B complex. Near the end of the G2 phase, the complex is inactivated due
to inhibitory phosphorylation of CDK1 by Wee1 (Tyr15) and Myt1 (Thr14 and Tyr15).
Cdc25 phosphatases dephosphorylate these sites to activate the CDK1-cyclin complex
(17). Inhibition of the Wee1 and Myt1 kinases induce mitotic entry of cells which have
been arrested in the S phase (23, 24).
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Plk family
In addition to the cyclin-CDK complexes, polo-like kinases play a major role in
cell cycle progression and control. The founding member of the family is the polo gene
that was first discovered and characterized in drosophila mutants with spindle pole
defects (25). After these findings, Plks have been characterized in eukaryotic cells. The
Plk family consists of five known members: Plk1, 2, 3, 4, and 5.
All Plk family members have the same basic structure, consisting of a
serine/threonine kinase domain at the amino terminus, and a regulatory portion,
consisting of the polo boxes in the carboxyl terminus as seen in Figure 3 (25, 26). The
Plk family members have either one (Plk5) or 2 (Plk1,2,3) or 3 (Plk4) polo-boxes.

Figure 1. Structure of Plk. The structure of Plks consist of the kinase domain and the
polo-box domain, containing one or more polo boxes, connected by a linker. Reprinted
by permission from Macmillan Publishers Ltd: Nature Reviews: Molecular Cell Biology,
Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division.
Nature reviews Molecular cell biology. 2004;5(6):429-40. 2004. (25)
The kinase domain is evolutionarily conserved among all members of the Plk
family. The unique feature of the Plk family is the complex of polo boxes, called the polo
box domain (PBD). The PBD binds to a serine or threonine site that has been

25

phosphorylated by another kinase or by a Plk itself – a process called priming.
Additionally, the PBD can bind to non-phosphorylated peptides such as Map205 (27).
Of the Plk family members Plk1 is the best characterized member, whereas the
functions of Plk2, 3, and 4 are not as well understood. In humans, Plk1 has been
primarily linked to the regulation of different events, mostly with the proper entry into
mitosis, the spindle assembly, and cytokinesis. Plk1 has also functions in the DNA
damage checkpoints (28). Plk2 is known as a tumor suppressor which functions in
centriole duplication and progression in G1-S of the cell cycle (29). Plk3 is known to
regulate the cell cycle, responses to various stresses, and disassembly of the Golgi
apparatus (30). Additionally Plk3 has tumor suppressor functions as well. Plk4 is also
known to function in centriole duplication and has regulatory roles in mitosis (31).
Recently, Plk5 has also been found which has lower catalytic activity, but has significant
functions in neurons (32).
A systematic evaluation of two screening databases, the Cancer Cell Line
Encyclopedia (CCLE), and Genomics of Drug Sensitivity to Cancer (GDSC) led to the
identification of Plk1 as a promising target for further investigation (33, 34). Plk1
emerged as the top candidate based on specific criteria: inhibition of the target must be
highly effective in a subset of NSCLC cell lines, the target should not extensively
studied in NSCLC, and the target must have inhibitors in development for potential
translational studies. Studies in non-selected, refractory NSCLC patients showed 4%
derived a significant benefit from Plk1 inhibitors (35). However, it is unclear why a small
subset of patients respond to Plk1 inhibitors. We sought to further investigate the effect
of Plk1 inhibition on NSCLC cell lines.
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Plk1 regulation
The activities of Plks are regulated by localization, phosphorylation and relative
abundance. For example, during prophase and metaphase, Plk1 is localizes to the
centrosomes and kinetochores, where it functions in the maturation of the centrosomes
and the spindle assembly checkpoint (36). Regulation primarily occurs through the
phosphorylation of target proteins involved in these pathways. The polo box domain is
crucial for Plk1 localization and activity, as mutations in residues have demonstrated
inability for Plk1 to localize to the spindle poles (32).
Plk1 is expressed from G2 to the end of mitosis when it is rapidly degraded. Plk1
has a short half-life, and is expressed from G2 to the end of mitosis when it is rapidly
degraded during anaphase. The degradation of Plk1 is triggered by APC/C (26).
Plk1 transcription is repressed during G1 and activated in G2 (26). RB and E2F
transcription factors repress Plk1 transcription. The DREAM complex and FOXM1
promote Plk1 transcription (26).
The kinase activity of Plk1 is observed mainly in the G2-M transition and peaks
during the M phase (25). Post-translational modification (phosphorylation) is reported to
be a major regulatory mechanism for Plk1. Phosphorylation of Plk1 results in its
activation. The activation of Plk1 has been proposed to work through priming
phosphorylation of binding partners by the CDK1-cyclin B complex which allows for the
binding of the PBD thereby uncoupling it from the kinase domain (37). It has been
reported in human cells that Plk1 activation occurs a few hours before entry into the
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mitotic phase (27). Phosphorylation of Ser128 (hinge region) and Thr210 (T loop) are
required for activity. Aurora A and its co-factor Bora phosphorylate Plk1at Thr210 (26).
This phosphorylation is a crucial step for Plk1 to start mitotic entry and in promoting
mitosis after G2 checkpoint arrest.

Plk1 and mitotic entry
One of the main functions of Plk1 is to facilitate mitotic entry. Mitotic entry is
regulated by the levels of the active CDK1-cyclin B complex. In G2, there is increased
activity of the cyclin B promoter and more stabilization of cyclin B mRNA levels as
compared to other phases of the cell cycle, leading to higher levels of protein (38).
Cyclin B is able to bind to the inactive CDK1, but the complex is initially inactive due to
phosphorylation by Wee1 and Myt1 (Fig. 4).

Figure 2. Role of Plk1 in Mitotic Entry. Plk1 facilitates mitotic entry by acting on
several substrates including cyclin B, Wee1, Myt1, and Cdc25. Reprinted by permission
from Macmillan Publishers Ltd: Oncogene, van Vugt MA, Medema RH. Getting in and
out of mitosis with Polo-like kinase-1. Oncogene. 2005;24(17):2844-59. 2005.(39)

28

CDK1 is phosphorylated by the Wee1 and Myt1 kinases on the ATP binding site
of Tyr15 and by Myt1 on Thr14. This phosphorylation prevents ATP from binding and
the transfer of the phosphate group for the kinase activity (39). Additionally, the complex
is regulated by the localization within the cell. For entry into mitosis, dephosphorylation
of the sites on the CDK1-cyclin B complex is crucial for complex activation. The
dephosphorylation is done by the members of the Cdc25 family of phosphatases (a, b,
and c). Plk1 regulates the activity of the Wee1 and Myt1 kinases along with the Cdc25c
phosphatase. Plk1 phosphorylates Myt1 and Wee1, primarily to inhibit them and also
marks Wee1 for degradation (39). Plk1 activates Cdc25c, promoting the activity of the
CDK1-cyclin B complex.

Plk1 and DNA damage response
Additionally, Plk1 plays a role in the DNA damage response. When DNA damage
occurs, cells are unable to proceed in mitosis until the DNA is repaired– a process
termed the G2 DNA damage checkpoint (28). Inactivation of Plk1 is a key mediator of
this G2 arrest. Before entry into mitosis, Plk1 is phosphorylated by Aurora A kinase
together with Bora, at the Thr210 site, activating it. Bora is able to open up the closed
formation of Plk1 and Aurora A is able to phosphorylate Plk1 for activation during the
mitotic entry. In response to the DNA damage, two kinases : ATM (ataxia talangectasia
mutated) and ATR (ATM and RAD3-related) are activated. ATM and ATR phosphorylate
Bora at Thr 501, causing it to be recognized by the E3 ubiquitin ligase for degradation
(28). Once degraded, however, Bora cannot facilitate the activation of Plk1 (28). As Plk1
is not able to be activated, CDK1 is unable to be activated, resulting in a G2 arrest.
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When DNA damage occurs in cells at the G2 phase, they avoid production of abnormal
chromosomes by not going into mitosis. Following DNA repair, Plk1 is again activated,
allowing for the mitotic entry and recovery of cell division.

Plk1 and the spindle assembly checkpoint (SAC)
The SAC is a process which ensures that the kinetochores of the chromosomes
are properly attached to spindle microtubules for proper cell division. It prevents the
start of anaphase until all kinetochores are attached properly to the microtubules
coming from the poles from the opposite sides of the parental cell (40). Plk1 functions to
relieve the inhibitory signal of the spindle checkpoint. During meta- and anaphase, Plk1
is localized to the chromatids, where it is required for stable attachment of kinetochores
to the microtubules of the spindle apparatus (36). Plk1 depleted cells which are also codepleted of surviving are not able to arrest, suggesting that Plk1 is crucial to producing
the tension on the kinetochores to start the spindle checkpoint signaling (41).
Additionally, Plk1 is known to phosphorylate the translationally controlled tumor
protein (TCTP) at Ser46 (42). TCTP is a highly expressed protein which is known to
have a function in a variety of cellular processes, one of which is stabilization of
microtubules (43). It is known to localize with other factors towards the spindle during its
assembly (44). Checkpoint proteins, including Mad and Bub and Mps1 kinase
negatively regulate the activity of the Anaphase-Promoting Complex (APC) by
inactivating Cdc20. Once the kinetochores and microtubules are properly attached,
these signals will deteriorate and the APC will activate. The degradation of securin,
which normally binds and inhibits the protease, separase, is an important step in
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promoting anaphase (45). Separase, which is now active, then cleaves the Scc1 (sisterchromatid cohesion-1) subunit of the cohesin complex, which results in the loss of
sister-chromatid cohesion. The chromatids now are able to separate in the anaphase
stage. The Cdc20 form of APC also targets cyclin B for degradation, leading to the
inactivation of CDK1 (36).

Plk1 in cancer
Plk1 was first reported to be associated with neoplastic growth based on studies
showing increased levels of Plk1 expression are increased in cancer. Plk1 is
overexpressed in different types of cancers including NSCLC, melanoma, colon, and
prostate cancers (46). While the expression of Plk1 is below the limit of detection in
most adult tissues, organs with an increased population of proliferative cells, such as
the thymus, spleen and testes, express detectable Plk1 at low concentrations (46). Plk1
overexpression leads to oncogenesis by causing chromosomal instability and other
aberrations in mitosis caused by checkpoint defects. Plk1 overexpression has also been
reported to transform NIH 3T3 cells in vitro and in vivo (47).

Plk1 inhibitors in cancer
Given its apparent role in neoplasias, several inhibitors of Plk1 activity have been
developed. In cancer cells, the silencing of Plk1 expression using RNA interference or
small molecule inhibitors results in various biological effects, including G2/M
accumulation, mitotic catastrophe, apoptosis, and senescence (48-50). Knockdown of
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Plk1 using siRNA in primary human cells reduces the rate of cell division but did not
increase apoptosis significantly (51, 52).
Small molecule inhibitors of Plk1 inhibitors have been developed as therapeutic
strategies for cancer. These Plk1 inhibitors are ATP competitive inhibitors that bind to
the ATP binding site of Plk1 and prevent its enzymatic activity. The Plk1 inhibitors
currently most advanced in clinical development are: BI2536, BI6727 (volasertib), and
GSK461364. All three are ATP-competitive kinase inhibitors. BI2536 and volasertib
(both from Boehringer Ingelheim) are dihydropteridinone derivatives. In cell culture
assays, BI2536 inhibits the proliferation of a variety of human cancer cell lines with
IC50 values ranging from 2 to 25 nM. Following treatment with BI2536, cancer cells are
arrested in pro-metaphase, stain positive for phospho-histone H3 indicating chromatin
condensation . These cells have also been reported to aberrant numbers of mitotic
spindles with unfocused poles, and have misaligned chromosomes on the mitotic
spindles . In addition to mitotic arrest, these treated cells undergo apoptosis as seen by
poly-(ADP-ribose) polymerase (PARP) cleavage, flow cytometry and TUNEL assays
(53).
However the effects on cancer cell lines are not uniform and some lines are
resistant to the effects of Plk1 inhibition or knock-down (48). Due to these varying
responses to treatment options, it is important to establish biomarkers of response to
different therapies. Currently, there are no established predictive biomarkers of
response for Plk1 inhibitors. Some potential biomarkers include p53 and KRAS. Tumors
with both p53 deficiency and high Plk1 expression may be more sensitive to Plk1
inhibitors, although some controversial data exist (31). p53 deficient cells have been
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reported to have decreased cell growth in comparison to p53 wild type cells after
treatment with small-molecule inhibitors of Plk1 (54).
On the other hand, in Plk1 expression may be essential for the proliferation of
KRAS mutant cancers because .However, detailed studies investigating the effects of
Plk1 inhibitors in KRAS mutant cancers have not been reported. In stably oncogenic
KRAS-G13D mutant colorectal cancer cells, cell death was increased by Plk1 depletion
using shRNA or treatment with the Plk1 inhibitor, BI2536 (52). KRAS mutant cells
treated with BI2536 accumulated in G2/M, suggesting that KRAS-mutant cells depend
more on Plk1 for mitotic progression than cells with wild type KRAS, and that KRAS
mutant tumors may respond well to drugs which inhibit Plk1.
BI2536 has been studied in Phase I and II clinical trials; however, it has not
shown sufficient levels of antitumor activity for further clinical development in solid
tumors. In single agent clinical trials of BI2536 in refractory solid tumors, a fraction of
patients respond: 14% urothelial (55), 4.2 % in NSCLC, 5% in advanced solid tumors
(55, 56). This has been caused, in large part, to poor pharmacokinetic properties, and
off target effects that result in the inhibition of Plk3, a tumor suppressor (57). In contrast,
volasertib has advanced from clinical trials and recently has been given “breakthrough
status” by the FDA after significant benefit was observed in treating acute myeloid
leukemia in combination with cytarabine (58). The results of a Phase I clinical trial for
GSK461364 have also been recently published (59).
Non-ATP competitive Plk1 inhibitors have been in development, primarily
targeting the polo box domain (60). The focus of these non-competitive inhibitors is on
minimizing the binding of phosphopeptides to the PBD, thus preventing the
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conformational change that opens up the kinase domain for further activation. These
inhibitors have not been extensively studied to date.

Plk1 inhibitors in NSCLC
Plk1 inhibitors have not been extensively studied in NSCLC. NSCLC patients
with higher levels of Plk1 expression have worse prognosis (60). Studies in nonselected, refractory NSCLC patients showed 4% of these patients had a significant
benefit from Plk1 inhibitors (35). The three Plk1 inhibitors which are most relevant
clinically are volasertib, GSK461364, and BI2536. Volasertib was found to have
antitumor activity against H460 NSCLC cell line in vitro and in mice (61). GSK461364
had antitumor activity against 2 of 3 NSCLC cell lines in mice (61). In 3 NSCLC cell
lines, BI2536 led to prolonged spindle assembly checkpoint and subsequent mitotic
catastrophe (62). BI2536 has been combined with pemetrexed in NSCLC and 2 of 33
patients had a partial response (61). Additionally, siRNA targeting Plk1 led to cell cycle
arrest and apoptosis of NSCLC cell line in vitro and decreased tumor growth in vivo
(63). It has been shown that Plk1 inactivation has antitumor activity in a small subset of
NSCLC cells. The observed effects of Plk1 inhibition in a subset NSCLC may be linked
to the epithelial or mesenchymal phenotypes often observed in NSCLC cell lines (64).

Epithelial to Mesenchymal Transition (EMT)
EMT is a process which was first characterized in embryonic development (65).
EMT allows an epithelial cell to lose its polarity, cell adhesion, and causes it to become
migratory and invasive, hence, becoming a mesenchymal cell. A mesenchymal cell has
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several properties, including that it is more mobile, invasive, and can evade
programmed cell death (66).

Figure 3. Epithelial to mesenchymal transition EMT is the transition of a polarized
epithelial cell into a mobile mesenchymal cell. Several factors play a role in this
transition. Reprinted by permission from AMERICAN SOCIETY FOR CLINICAL
INVESTIGATION: Journal of Clinical Investigation, Kalluri R, Weinberg RA. The basics
of epithelial-mesenchymal transition. The Journal of Clinical Investigation.
2009;119(6):1420-8. 2009. (67)
EMT and its reverse process, the mesenchymal to epithelial transition (MET) are very
important in several developmental processes including gastrulation, neural crest
formation, and myogenesis (68). It is also extremely important in wound healing, and
plays a role in metastasis of cancer. The loss of the protein E-cadherin is a crucial
event of EMT (67). Several transcription factors including Snail and ZEB1 inhibit Ecadherin by binding to its promoter and inhibiting its transcription. The miR-200 family of
micro RNAs are known to directly target mRNA of repressors of E-cadherin, such as
ZEB1 (69). Other transcription factors can repress tight-junction related proteins
including claudins and desmosomes which also enhances EMT (67).
Additionally, signaling pathways including TGF- β, FGF, EGF, HGF, Wnt and βcatenin and Notch have been known to facilitate EMT transitions (70). RAS and MAPK
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pathways have been shown to activate the transcription factors Snail and Slug (71).
TGF-β is a significant inhibitor of epithelial cell proliferation and primary cell
tumorigenesis. It can also serve as a positive regulator of tumor progression and
metastasis (72). In vitro studies have demonstrated that TGF-β can induce an EMT in
certain types of cancer cells by way of Smad-protein mediated signaling (73). Through
ligand binding with the TGF- β receptors, Smad family proteins are activated and form a
complex which translocates into the nucleus of cells to transcriptionally regulate target
genes (74). This signaling can activate transcription factors which promote EMT. TGF- β
signaling induces expression of micro RNAs which repress epithelial proteins.
Additionally, TGF- β can induce pathways which are not related to Smad signaling
which still contribute to EMT. These include activation of the PI3K-AKT pathway
signaling, as well as regulation of Rho-GTPases which are involved in cell junction
destruction (74).

EMT and cancer
EMT is known to play roles in both development and in cancer. The primary
difference between the two is that in normal cells, these events are highly regulated,
both spatially and temporally, where in cancer cells, such processes are not strictly
regulated and can bypass certain events and checkpoints (75). During tumorigenesis
(Figure 4), EMT helps cancer cells become more motile and invasive (67). The
transformation to malignancy is associated with signaling pathways which promote
EMT.
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Figure 4. Epithelial to mesenchymal transition in cancer Cancer cells undergoing
EMT have to go through several stages to invade and establish in a secondary site.
Reprinted by permission from AMERICAN SOCIETY FOR CLINICAL INVESTIGATION:
Journal of Clinical Investigation, Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition. The Journal of clinical investigation. 2009;119(6):1420-8. 2009.
(67).
The growth of neoplastic cells after transformation is quite slow, and for the
tumor to grow to a certain size, it needs to vascularize (76). Invasion of the stromal cells
of the host is important for the tumor to replenish the nutrients and other factors needed
to survive (76). Epithelial to mesenchymal transitions facilitate this process, as the
primary cells are more invasive and motile and are able to break through the basement
membrane and are able to enter the bloodstream (67). As the cells are able to enter the
bloodstream, they are able to adhere to other cells, eventually escape, and establish a
secondary tumor at a distant site.

EMT and cell cycle
Few studies have linked the important features of cancer, EMT and the cell
cycle. These reports suggest that upregulation of some Rho GTPases can increase
the invasive capabilities of cancer cells. These Rho GTPases, known to have functions
in deteriorating cell junctions and cytoskeletal changes, have been reported to
downregulate cyclin A2, which binds to CDK2 and CDK1, important in S phase and
G2/M phase progression, respectively (77). Additionally, TGF-β, a known inducer of
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EMT is known to induce survivin, which stabilizes Aurora B. Aurora B is a kinase which
plays an important role during the cell cycle by activating Plk1 (78).

The link between EMT and Plk1 has not been explored and needs to be
elucidated further in NSCLC. Based on gene and protein expression in NSCLC cell lines
in our study, EMT related genes and proteins were significantly correlated with
response to Plk1 inhibition. In this thesis, we examine the responses of NSCLC cell
lines to Plk1 inhibition. We then proceed to look at the biological effects of Plk1
inhibition on NSCLC cell lines. Finally, we assess the relationship of gene and protein
expression to Plk1 inhibitor sensitivity to find predictive biomarkers of response to Plk1
inhibition.
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Chapter 2: Materials and Methods
This chapter is based upon our submitted manuscript entitled “Epithelial-Mesenchymal
Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell
Lung Cancer” which is currently under review.
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Antibodies and reagents
The following antibodies were used: anti- Plk1 (Invitrogen); phosphorylated Myt1
(Thr495) and Myt1 (Thermo Scientific); phosphorylated CDK1 (Tyr15), FOXM1, PARP,
cleaved PARP, phosphorylated translational controlled tumor protein (TCTP) (Ser46),
Cyclin B, E-cadherin, TCTP, vimentin, β-catenin, and ZEB1 (Cell Signaling Technology);
and β-actin (Sigma). The Plk1 inhibitors BI2536, volasertib, and GSK461364 and Pglycoprotein inhibitor PSC-833 were purchased from Selleck Chemicals (Houston, TX)
and prepared as 10 mM stock solutions in dimethyl sulfoxide. We used predesigned
sets of 4 independent siRNA sequences of the target genes PLK1 and CDH1
(siGENOME SMARTpool, Dharmacon, Thermo Scientific, Pittsburgh PA). The human
TGF-β1 was purchased from Cell Signaling Technology.
Cell culture and characterization
Sixty three human NSCLC cell lines were authenticated with DNA fingerprinting,
routinely tested for Mycoplasma spp., and maintained as previously described (79). The
cell line Cal-12T was purchased from DSMZ. The cell lines’ mutational profiles for 264
genes (Supplemental Table 1) were obtained from the catalog COSMIC (version 67)
and the Cancer Cell line Encyclopedia. Baseline mRNA (48,804 probe sets) and
protein (193 proteins and phosphoproteins) expression levels were determined using
Illumina and reverse phase protein arrays, respectively, as previously described (80,
81).
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Cell viability assays
Fifty NSCLC cell lines were incubated with dimethyl sulfoxide (vehicle control), BI2536,
or volasertib for 120 h at nine distinct concentrations, with the maximum dose being the
peak concentration of each drug in humans (Cmax): 1.6 µM for BI2536 and 1.2 µM for
volasertib. Cell viability was measured using the MTT assay as previously described
(82). For GSK461364, 63 NSCLC cell lines were incubated with dimethyl sulfoxide or
GSK461364 for 72 h at seven distinct concentrations, with the maximum dose being the
Cmax (1 µM). CellTiter-Glo luminescent cell viability assay (Promega) was performed per
the manufacturer’s specifications. For both assays, six replicates were tested each
concentration, and each test was completed at least twice on different days.
For colony formation assays, cells were treated for 24 h with dimethyl sulfoxide or
volasertib and then incubated in drug-free medium for 14 to 21 days. Plates were
stained with crystal violet, and total colony area per well was estimated using ImageJ
software as previously described (79, 83).

Calculation of the drugs’ effects on viability
IC50 and IC70 values were estimated from the best-fit dose-response model selected
by calculating residual standard error using the R packages Dose Finding and drc
(84). For many cell lines, the dose-response curve plateaued at or near the IC50, so we
used IC70 values to distinguish sensitive and resistant cell lines. Cell lines with IC70
values greater than the Cmax were considered resistant; cell lines with IC70 values less
or equal to the Cmax were classified as sensitive.
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Statistical analysis
IC50 and IC70 values were estimated from the best-fit dose-response model selected
by calculating residual standard error using the R packages Dose Finding and drc (84).
Gene expression data were available for 43 of the 50 cell lines treated with BI2536 and
volasertib and 50 of the 63 lines treated with GSK461364. Forty-one cell lines had gene
expression and drug sensitivity data for all 3 drugs. Reverse phase protein array
(RPPA) data were obtained as previously described and available for 44 lines tested
with BI2536 and volasertib and 45 lines tested with GSK461364 (80, 81). For the cell
lines that were consistently sensitive or resistant to all 3 drugs (universal group), gene
expression data were available for 10 sensitive and 11 resistant lines, and protein
expression data were available for 10 sensitive and 13 resistant lines.
To compare gene and protein expression patterns between resistant and sensitive lines,
two-sample t-tests were performed on a gene-by-gene or protein-by-protein basis. To
adjust for multiple testing, we applied the beta-uniform mixture model to modelling P
values in order to select an appropriate false discovery rate cutoff (85). For correlations
between drug sensitivity and gene mutations, we performed Fisher exact test.
Additionally, associations between drug sensitivity and epithelial-mesenchymal
transition (EMT) scores (80) were evaluated using two-sample t-tests.
To evaluate pre-established signatures for KRAS dependency (64) and chromosomal
instability (86), we applied a two-way hierarchical clustering technique to the dataset in
order to produce heat maps (80). We tested correlation between the sensitivities of
three drugs using the chi-square test. For assessment of association between each
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pair of drugs, we performed the Fisher exact test. All statistical analyses were
performed using R software (87).
Pathway analysis was performed with the Ingenuity Pathway Analysis tool
(http://www.ingenuity.com/) using gene sets as described in the Results section.
Cell cycle analysis and apoptosis assays
For cell cycle analysis, cells were harvested, fixed, incorporated with
bromodeoxyuridine (BrdU) and stained with 7-aminoactinomycin D (7AAD) (BrdU Flow
kit; BD Biosciences). DNA content was analyzed with a cytofluorimeter, a fluorescenceactivated cell sorter (FACScan; Becton Dickinson), and the ModFit software program
(Verity Software House) (79). To measure apoptosis, we used TUNEL (terminal
deoxynucleotidyl transferase dUTP nick end labeling) staining (APO-BrdU kit; BD
Biosciences) and quantitated bromodeoxyuridine incorporation by fluorescenceactivated cell sorting (BrdU Flow kits; BD Biosciences) according to the manufacturers’
protocols.
Western blotting
For Western blots, sub-confluent cells were lysed on ice, and the lysates were
centrifuged at 20,000g for 5 min at 4°C as described previously (79). Whole-cell lysates
containing 30 to 50 μg of proteins were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis, immunoblotted with the indicated primary
antibodies, and detected with horseradish peroxidase-conjugated secondary antibody
(Bio-Rad Laboratories) and an enhanced chemiluminescence reagent (Amersham
Biosciences).
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Transient Transfection
Cultured cells were plated in six-well plates 24 hours prior to transfection. On the
following day, cells were transfected RNA iMax. siRNA was mixed with the reagent in
serum free media. Liposomal complexes were formed in the serum free media and
incubated at the room temperature for five minutes. The mixture was then added to the
indicated wells and incubated for the indicated time points.
Inducible miR-200 Transfections
A modified doxycycline-inducible pTRIPz-RFP vector expressing miR-200a, miR-200b,
or both (miR-200ab) was generously provided by Dr. Gregory Goodall at the University
of Adelaide. H157 NSCLC cells were transduced by Lipofectamine LTX or lentiviral
delivery of pTRIPz–miR-200, ZEB1B or a control vector. Lentiviruses were produced
by cotransfecting HEK-293 cells with 1.5 µg of the viral packaging vector psPAX2, 0.5
µg of the viral envelope vector pMD2.G, and 2 µg of pTRIPz–miR-200 or the control
vector using Lipofectamine LTX. HEK-293 cell medium was changed 24 h after
transfection, and the cells were incubated at 37oC for 48 h to allow for virus
production. After 48 h, HEK-293 media containing virus particles were transferred onto
H157 NSCLC cell culture plates and incubated at 37oC for 48 h. After transduction,
fresh RPMI 1640 medium with 10% FBS was added to the H157 cell culture plates, and
the cells were allowed to recover for 24 h. Cells were selected using 3 µg/mL
puromycin, and 2 µg/mL doxycycline was used for induction of miR-200 and
RFP. Induced RFP expression was used to visually verify successfully infected
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cells. H1299 cells expressing miR-200 were sorted using flow cytometry for RFP
positivity to obtain the transfected cell population.
H1299 cells were transfected with 4 µg of pTRIPz–miR-200 or the control vector using
Lipofectamine LTX. After 24 h of transfection, cells were selected using 3 µg/mL
puromycin in RPMI 1640 with 10% FBS. Expression of miR-200 and RFP was induced
with 2 µg/mL doxycycline. H1299 cells expressing miR-200 were sorted using flow
cytometry for RFP positivity to obtain the transfected cell population.

Immunofluorescence Microscopy
Cells were plated on MilliCell EZ-Slides (Millipore). After 24 hours, the cells were treated
with vehicle or volasertib for the time points indicated. Following treatment, cells were
rinsed with PBS, fixed with 4% paraformaldehyde. After washing, the samples were
blocked in 1% BSA, and primary antibody was added. Slides were kept overnight in
4°C. Afterwards, the cells were washed, and were incubated with the secondary
antibody for one hour, protected from light. After washing, mounting media with DAPI
was added along with coverslips. Slides were visualized using a fluorescence
microscope.

H&E staining
Cells were plated on MilliCell EZ-Slides (Millipore). After 24 hours, the cells were treated
with vehicle or volasertib for the time points indicated. Following treatment, the cells
were washed with PBS, fixed with 4% paraformaldehyde. Then cells were stained with
hematoxylin for one minute, washed with tap water for bluing. Following this, cells were
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dehydrated with increasing concentrations of ethanol. Cells were then stained with
eosin for one minute, and excess eosin was removed by ethanol washing. Following
this, slides were air-dried and mounted with DPX.

ELISA Plk1 activity assay
A Plk1 ELISA assay from MBL Technologies was used to assess Plk1 activity after
treatment with volasertib. Briefly, subconfluent cells were pre-treated with the inhibitor
for the indicated time points, harvested, lysed, and used immediately afterward for the
assay. The concentration of the protein was quantified using the Bradford method and
added to the ELISA plate coated with the substrate. After incubation to bind the
substrate, there was incubation with the kinase buffer, followed by incubation with the
primary anti-phospho-threonine antibody. This was followed by incubation with the
HRP-linked secondary antibody, which was then detected after incubation with HRP
substrate, and the optical density was measured at a wavelength of 450nm.

Doubling Time (DAPI)
Cells were seeded in a 384 well plate at different densities ((125 cells/well, 250
cells/well, 500 cells/well, 1000 cells/well and 2000 cells/well). After one day, the cells
were fixed in 1% paraformaldehyde for 10 minutes. Following fixation, DAPI was added
to the cells and cells were counted using an INCELL analyzer. This was repeated at 48,
72, and 96 hour time points. The averages and standard deviations are calculated, and
the doubling time was calculated using the following equation: 3*(LOG(2)/LOG(96h Std
Dev. /48h Std Dev.)).
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Kaplan Meier Plotter
For Kaplan Meier analysis, we used Kaplan Meier Plot software analysis from
www.kmplot.com (88). We used the latest 2015 version of the database generated from
1926 lung cancer patients. In our analysis, we included adenocarcinomas and
squamous carcinomas, with stage III/IV disease; we did not restrict based on gender,
and smoking status.
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Chapter 3. Results
This chapter is based upon our submitted manuscript entitled “Epithelial-Mesenchymal
Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell
Lung Cancer” which is currently under review.
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Plk1 overexpression correlates with poor survival in lung patients
To enforce Plk1 as a target for further study, we determined the correlation of Plk1
mRNA expression and progression free survival in 2435 lung cancer patients. Using
the Kaplan Meier Plotter, we utilized microarray data which had been published from the
caArray project, Gene Expression Omnibus (GEO), and The Cancer Genome Atlas
(TCGA) (88). Patients were not differentiated based on smoking history or gender.
There was a significant relationship (p = 4.8e-15) between high Plk1 mRNA expression
and lower survival (Fig. 5). To determine the cutoff for the gene, the percentile of
expression between the lower and upper quartiles were computed, and the best
predictive threshold was used as the cutoff through univariate Cox regression (88).
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Figure 5. High Plk1 mRNA expression correlates with lower progression free
survival in lung cancer patient samples. Kaplan Meier curve showing the Plk1 mRNA
expression and progression free survival generated from www.kmplot.com. (n = 2435
patients).
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NSCLC cell lines have diverse sensitivities to Plk1 inhibitors
The Genomics of Drug Sensitivity in Cancer contains drug sensitivity data on 14
NSCLC cell lines treated with 2 Plk1 inhibitors (Fig.6a) (89). To enhance future clinical
translation, we used the three most clinically advanced Plk1 inhibitors, BI2536, BI6727
(Volasertib), and GSK461364. We tested 50 NSCLC cell lines for sensitivity to BI2536
(Cmax 1.6 μM) and volasertib (Cmax 1.2 μM) using MTT viability assays. To validate
our findings, we also separately tested 63 NSCLC lines with GSK461364 (Cmax 1.0
μM) using CellTiter Glo assays (GSK461364 was tested by Drs. Uma Giri and Shaohua
Peng, in collaboration with Dr. John Heymach’s lab). Dose response curves were
generated for these data and distinct groups were observed (Fig. 6b). Cell lines’
sensitivity to the drugs varied widely. In many cell lines, the dose response curves
plateaued near the IC50. To better distinguish the sensitive and resistant cell lines, we
used the IC70 values. Those cell lines which had IC70 values which were lower than
the Cmax for the drug were considered sensitive and those which did not reach the
IC70 value prior to the Cmax were considered resistant which resulted in a dichotomous
population.
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Figure 6. NSCLC cell lines have diverse sensitivities to Plk1 inhibition. (A) Drug
sensitivity for two Plk1 inhibitors in 14 NSCLC cell lines was obtained from the GDSC
online database (left). Each data point indicates the IC75 values for one individual cell
line. NSCLC cell lines were treated with BI2536, volasertib, or GSK461364 for 72-120
h, and viability was estimated using MTT or CellTiter-Glo assay. Each data point
indicates the IC70 for one individual cell line. The horizontal blue line on each chart
represents the Cmax value for each drug, which was used as the cutoff for sensitivity.
(B) Replicate data were graphed for each concentration, and the best dose-response
model was selected by the residual standard error (RSE) method (84). The horizontal
blue line on each dose response curve represents the IC70. The GSK461364
compound was screened by Drs. Uma Giri and Shaohua Peng in collaboration with Dr.
John Heymach’s laboratory. Dose response curves were generated in collaboration with
the Bioinformatics Department, including Drs. Pan Tong, Suk-Young Yoo, and Jing
Wang.
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We then examined the correlation between the sensitivities drug to drug.
Sensitivities to the three drugs were correlated at a p-value of 1.4e-06 (chi-square test).
When drug sensitivities were compared pair-wise by the Fisher exact test, the
correlation between BI2536 and volasertib (p = 1.1e-06), was stronger than that the
correlation between GSK461364 and volasertib (p = 0.186) or between GSK461364 and
BI2536 (p = 0.020). This result was expected given these drugs’ structural and
chemical similarities. To ensure that the observed sensitivity differences were not due
to technical differences between the MTT and CellTiter-Glo viability assays, we tested
the universal lines for sensitivity to all three drugs using identical conditions. Although
the IC70 values were not absolutely identical between the two assays, all the universal
cell lines remained in the same category (sensitive or resistant) regardless of the assay
used (Table 2).
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Table 2. MTT and CellTiter-Glo assays confirmed universal sensitive and
universal resistant cell lines to three Plk1 inhibitors. After screening all cell lines we
assayed the cell lines which were either sensitive to all three inhibitors (universally
sensitive) or resistant to all three inhibitors (universally resistant) using both MTT and
Cell TiterGlo assays. The IC70 values obtained are shown above. IC70 values were
generated with the help of the Bioinformatics Department, including Drs. Pan Tong,
Suk-Young Yoo, and Jing Wang.
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BI2536, volasertib, and GSK461364 inhibit Plk1 targets in NSCLC cell lines
To determine if BI2536, volasertib, and GSK461364 are indeed inhibiting Plk1 in
the NSCLC cell lines, we used two universally sensitive cell lines, H1792 and Calu-6,
and two universally resistant cell lines, H322 and H358, to study the effects of Plk1
inhibition on known Plk1 targets. We examined the phosphorylation of Myt1 kinase at
the inhibitory phosphorylation site of Thr495 for H1792 and H322 and phosphorylation
of TCTP at Ser46 for all four cell lines, which are both known phosphorylation targets of
Plk1 at different concentrations and time points. We examined the dose dependent
response to determine the relevant dose needed to inhibit Plk1 in the cell lines (Fig. 7a),
which we determined to be 50nM. We were able to see target inhibition persist up to
120 hours, which mirrored the maximum time interval we exposed the cell lines to the
drugs in the viability assays (Fig. 7b). As we expected, inhibition of Plk1 led to a
decrease in phosphorylation of Myt1 in the NSCLC cell lines. We additionally observed
that although TCTP phosphorylation after treatment, the decrease was much lower in
the two resistant lines tested. We observed an increase in the levels of phospho-CDK1
at Tyr15, indicating an inactive CDK1 after Plk1 inhibition using volasertib. Additionally,
we were able to see stabilization of levels of cyclin B after Plk1 inhibition (Fig 7c).
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Figure 7. Inhibition of Plk1 substrates after treatment with Plk1 inhibitors. NSCLC
cell lines were incubated with dimethyl sulfoxide (vehicle control), BI2536, volasertib, or
GSK461364 using the indicated concentrations for 2 h (A, B) or at 50 nM for the
indicated periods (in hours) (D). Cells were then lysed and subjected to Western
blotting (A-D) with the indicated primary antibodies and (B) p-TCTP band density was
quantitated.

We noticed in the dose response western blots that there was incomplete target
inhibition at higher doses, in regards to GSK461364. To test whether the drug was
being actively pumped out by the cells, we also examined ATP binding cassette (ABC)
protein expression that has been reported to be possible resistance mechanism for Plk1
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inhibition (90). We observed that GSK461364 induced ABCC1 and ABCG2 expression
at high concentrations (Fig. 8).

Figure 8. Plk1 inhibition with GSK461364 led to increase in ABCB1 and ABCC1
protein expression. Cells were incubated for 4 hours with 50nM GSK461364, lysed,
and protein expression was analyzed through Western blot.

Plk1 inhibition leads to lower Plk1 kinase activity in NSCLC cell lines
To more directly test if Plk1 inhibitors were inhibiting Plk1 function, we assayed
for Plk1 enzyme activity using an ELISA based assay that measures the
phosphorylation of protein-X, a substrate of Plk1. Plk1 activity was decreased up to
80% with concentrations of 50 nM and 1 µM volasertib in extracted cell lysates to which
inhibitor was added directly to the lysates (Fig 9a). NSCLC cell lines were incubated
with 50nM volasertib for 24 and 48h time points. In intact cells, we observe a lower
inhibition efficiency at short time points, and incomplete inhibition in resistant cell lines
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(Fig. 9b). However, in experiments in which volasertib was added to the intact cells,
volasertib was not added to the lysates incubated with the Plk1 substrate.
A

Plk1 Activity in Cell Lysates
Relative Activity (Fold Control)

1.2
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*
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Relative Plk1 Activity per ug Protein
(Fold Control)

Plk1 Activity in Pretreated Cells
1.2
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0.6
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*
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*

*

0.4
0.2
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Figure 9. Plk1 activity assay demonstrates inhibition of Plk1 kinase activity in 2h
treated lysed cell extracts, and at 24 and 48h time points in pretreated cells. Plk1
activity was assayed using an ELISA kit. Cells were either treated after lysis for four
hours (A) or after treatment (B) with volasertib for the indicated time points. (C is vehicle
control, T is treated with 50nM volasertib). Asterisks represent significant differences (p
< 0.05) for the treated samples compared to the controls.

Plk1 inhibition leads to inhibition of colony formation in sensitive cell lines
In the cell line screening, the cells were incubated for the complete time period
with the drug. To measure if the effects of Plk1 inhibition in NSCLC cell lines were
irreversible, we incubated two sensitive and two resistant NSCLC cell lines with 50 nM
volasertib for 24 hours and measured colony formation 14-21 days later. Mirroring our
results from the viability assays, the sensitive cell lines H1792 and Calu-6 had
irreversible cell growth and inhibition of colony formation compared to the resistant cell
lines H322 and H358 (Fig. 10a). As another marker for cell proliferation, we also looked
at the effects of Plk1 inhibition on average colony size. Similarly to what is observed in
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the total area, the average colony area decreases in sensitive and resistant NSCLC cell
lines. Sensitive NSCLC cell lines have significantly greater reduction of average colony
area at low concentrations (Fig 10b).

B

A

62

63

C

Figure 10. Sensitive cell lines show greater colony formation inhibition compared
to resistant cell lines after 24h pulse treatment of volasertib. After 24h pulse
treatment, there was a reduction in the cell colonies growing in the assay wells (given
here as colony area in A) in the sensitive cell lines. As an additional measure of colony
growth, average colony area was quantitated (B) for a sensitive cell line (Calu-6) and a
resistant cell line (H322). There was significant (p < 0.05) decrease in average colony
size compared to controls for Calu-6 at lower concentrations of the inhibitor compared
to H322. (C) A representative scanned image of a sensitive cell line and a resistant cell
line. *, P < 0.05 compared to control or as indicated.
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Plk1 inhibition increases cells with 4N DNA content in NSCLC cell lines
The effect of Plk1 inhibition in the cell cycle has been widely reported and known
to cause prometaphase arrest (31, 53, 61, 91). We observed an accumulation of cells
with 4N DNA content as well as an increase in cells with greater than 4N DNA content
(Fig.11a-b). Additionally, there was a significantly increased sub G0 population of cells
in the sensitive cell lines compared to the resistant cell lines. To confirm the finding of
more polyploid cells after treatment, we used DAPI staining using immunofluorescence
to locate multiple nuclei within single cells (Fig. 12a). Similar results were seen using
brightfield microscopy after H&E staining (12b). In addition, we observed increased
nuclear chromatin condensation in the sensitive cells after treatment with volasertib
(12b), a marker of apoptosis (92). We found that there was an increase in polyploid cells
post treatment with Plk1 inhibitor volasertib in resistant NSCLC cell lines.
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A

66

B

Figure 11. Plk1 inhibition causes an accumulation of cells with 4N DNA content in
sensitive and resistant cell lines. After Plk1 inhibition, there was an accumulation of
cells with 4N DNA content after 24 and 48 hours for all cell lines. Sensitive cells had an
increased sub-G0 population after treatment, and resistant cells had increased number
of cells with >4N DNA content (A). A representative profile with gating is given for the
resistant cell line H358 and sensitive cell line Calu-6 (B).
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Figure 12. Plk1 inhibition increases the number of polyploid cells in resistant
NSCLC cell lines. The cells were visualized using immunofluorescence microscopy (A)
and brightfield microscopy (B) after treatment and staining. After quantitation (C), we
observed an increase in the number of cells with more than one nucleus in the resistant
cell line.
Plk1 inhibition leads to apoptosis in NSCLC cell lines
We also measured cell apoptosis in the two sensitive and two resistant lines.
From the TUNEL assay, we were able to see that the sensitive NSCLC cell lines H1792
and Calu-6 underwent significantly more apoptosis after 72 hour incubation with
volasertib (Fig 13a). In comparison, the resistant H358 and H322 cell lines underwent
less apoptosis compared to the sensitive cell lines. The results were validated using
another marker of apoptosis, western blotting for cleaved PARP. Here we found an
increase in cleaved PARP after treatment to Plk1 inhibitor volasertib in the two sensitive
cell lines (Fig. 13b-c).
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Control)

Cleaved PARP - Volasertib
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Figure 13. Plk1 inhibition causes significant apoptosis in sensitive cell lines but
not resistant cell lines. After 72h treatment with volasertib, sensitive cell lines
underwent significantly more TUNEL staining (A) and PARP cleavage (B) compared to
resistant cell lines (p<0.05). (C) Cleaved PARP bands were quantified using
densitometry and adjusted for loading with β-actin. *, P < 0.05 compared to control or as
indicated.
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Plk1 knockdown leads to cell cycle arrest and increased apoptosis in NSCLC cell
lines
To address the question of specificity of the inhibitors, we used Plk1 specific
siRNA to knockdown Plk1 and study the effects on the cell cycle. We found that Plk1
knockdown after 24 and 48 hours caused an accumulation of cells with 4N DNA content
in the NSCLC cell lines, as well as an increased sub G0 population in sensitive cell lines
(Fig. 14). Additionally, we observed that there was an increase in the number of cells
undergoing apoptosis after 72 hours of the Plk1 knockdown. PARP cleavage and
TUNEL positive cells was also increased in sensitive cell lines compared to the resistant
cells tested after Plk1 knockdown (Fig. 15).
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A
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B

Figure 14. Plk1 knockdown using siRNA causes an increase in 4N cells. We
observed an increase in sub-G0 cells in the sensitive cells while we observed an
increase in polyploid cells in the resistant cells after Plk1 knockdown (A). Gated cell
cycle profiles are given for a sensitive cell line Calu-6 and resistant cell line H322 after
knockdown (B).
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Figure 15. Plk1 knockdown causes significant apoptosis in NSCLC cell lines.
Plk1 knockdown causes an increase in TUNEL positive cells (A) and cleaved PARP (B)
in sensitive NSCLC cell lines. (C) Cleaved PARP bands were quantified using
densitometry and adjusted for loading with β-actin. *, P < 0.05 compared to control or as
indicated.
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Doubling time does not correlate with Plk1 inhibition sensitivity
Theoretically, cells which cycle faster should go through G2 of the cell cycle more often
and may be vulnerable to inhibition of Plk1. We studied if cell doubling time plays a role
sensitivity because Plk1 affects the cell cycles and cells that divide faster will go through
the cell cycle more times than slower growing cells during the assays. These cells with
shorter doubling time would therefore be in G2 for an increased time period, causing
them to be more vulnerable to Plk1 inhibition. We measured the doubling time of 9 (5
resistant, 4 sensitive) NSCLC cell lines. Using a two-sample t-test, there was no
significant difference between the average doubling time and IC70 for the three Plk1
inhibitors tested (Fig. 16).
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Average Doubling Time
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Figure 16. Doubling time did not correlate with sensitivity to Plk1 inhibition.
Doubling time was measured based on growth curve assays done by Dr. Uma Giri from
Dr. John Heymach’s laboratory. Cell lines were grouped based on the definition of
sensitive and resistant from the screening. There was no significant difference (p >
0.05) between the sensitive cell lines and resistant cell lines for each of the inhibitors
tested.
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NSCLC cell lines with RAS mutations are more sensitive to Plk1 inhibition than
those with wild-type RAS
As KRAS mutations had been implicated with sensitivity to Plk1 inactivation (52,
64), we examined the correlation between gene mutations for 264 genes that are
commonly associated with cancer and drug sensitivity for all cell lines treated with
BI2536 and volasertib and for 63 cell lines treated with GSK461364. To be able to
statistically analyze the RAS mutant cell lines, we grouped together the KRAS and
NRAS mutant lines so as to have a larger sample size. More NSCLC cell lines with RAS
mutations were sensitive to Plk1 inhibition than those with wild-type RAS (Table 3). No
mutation other than RAS correlated with sensitivity for more than one drug. We
examined co-occurrence of other mutations within the RAS mutant population because
co-mutations may define subgroups with distinct clinical outcomes and drug
sensitivities. We did not find any statistical correlation between Plk1 inhibitor sensitivity
and the presence of LKB or TP53 mutations within RAS mutant tumors possibly
because the numbers of cell lines within these subgroups was small.
To further characterize the KRAS mutants, we applied an established KRAS
dependency signature to KRAS mutant NSCLC cell lines (64). KRAS-dependent
NSCLC cell lines, defined as those that undergo apoptosis when KRAS is knocked
down, demonstrated classical epithelial morphology, whereas KRAS-independent cells
demonstrated a mesenchymal phenotype (64). In an unsupervised analysis, KRASindependent cell lines clustered in the sensitive group for GSK461364 (p of 0.0052) but
not for the other 3 groups (Fig. 17).

77

Gene and
drug
sensitivity

No. of cell lines
Mutant

P

Wild type
Resistant

Sensitive

(Fisher
test)

Resistant

Sensitive

Universal

5 (38%)

8 (62%)

9 (81%)

2 (19%)

0.04718

BI2536

9 (35%)

17 (65%)

18 (75%)

6 (25%)

0.005402

Volasertib

8 (31%)

18 (69%)

16 (67%)

8 (33%)

0.02248

GSK461364

20 (63%)

12 (37%)

22 (71%)

9 (29%)

0.595

RAS

Table 3. Cell lines with RAS mutations are more sensitive to Plk1 inhibition for
BI2536 and volasertib, but not GSK461364. Cell lines with KRAS and NRAS
mutations were grouped together to form a RAS mutant group. Cells with RAS
mutations (KRAS or NRAS) were more sensitive (p<0.05) to Plk1 inhibition for BI2536
and volasertib, but not GSK461364 (p>0.05).
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Figure 17. Genes associated with KRAS dependency correlate with sensitivity to
GSK461364. In an unsupervised analysis, KRAS independent cells clustered in the
sensitive region (p = 0.0052) for GSK461364, but not for the other two inhibitors or the
universal lines. We generated heatmaps using an established KRAS-dependency
signature (64) in KRAS mutant NSCLC cell lines with the help of the Bioinformatics
department (Drs. Suk-Young Yoo, Pan Tong, Jing Wang) (64). Out of the 44 genes in
the signature, we identified 31 genes with 42 probes in our gene expression data. The
following numbers of cell lines were identified with expression data available for the
genes of interest: for BI2536, 7 sensitive and 11 resistant cell lines; for volasertib, 11
sensitive and 5 resistant cell lines; for GSK461364, 12 sensitive and 17 resistant cell
lines; and for all three drugs, 9 sensitive and 4 resistant cell lines.
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TP53 mutation and the expression of ABC transporters do not correlate with
response to Plk1 inhibition in NSCLC cell lines.
In order to validate candidate biomarkers of response according to the available
literature, we tested correlation of TP53 mutational status (Fisher exact test), and gene
expression of ABC transporters ABCB1 and ABCG2 (two-sample t test) with sensitivity
to the three Plk1 inhibitors (Fig 18). No statistically significant correlation was found
(P>0.05).

Figure 18. Expression of ABC transporter proteins did not correlate with
sensitivity to Plk1 inhibitors. The gene expression of ABC transporter proteins
ABCB1 and ABCG2 did not correlate with sensitivity to the Plk1 inhibitors tested
(p>0.05).
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Mesenchymal NSCLC cell lines are more sensitive to Plk1 inhibition than
epithelial NSCLC cell lines
To determine why NSCLC cell lines had diverse sensitivities to Plk1 inhibition, we
examined the relationship between drug sensitivity and basal gene/protein expression in
four groups of cell lines: BI2536-sensitive/resistant, volasertib-sensitive/resistant,
GSK461364-sensitive/resistant, and the universal cell lines. We found that the
expression levels of several genes and proteins correlated with sensitivity to the Plk1
inhibitors (Fig. 19).
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Figure 19. Baseline mRNA and protein expression correlates with sensitivity and
resistance in universal cell lines. Shown are heatmaps of baseline gene expression
after supervised clustering of the universal cell lines at FDR of 0.2 (n = 91 genes) and
baseline protein expression after supervised clustering of the universal cell lines at FDR
of 0.3 (n = 8 proteins).

We hypothesized that genes that were found in all four groups and that had the
biggest differences in expression between resistant and sensitive cell lines would be the
most likely to be involved in sensitivity specifically to Plk1 inhibition rather than to be
involved in off-target drug effects. After correction for multiple comparisons, no gene
expression levels correlated with sensitivity to BI2536 or volasertib. We discovered that
the expression levels of several genes and proteins correlated with drug sensitivity
(Table 4, 5).
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Gene
Probe ID
Symbol
ILMN_1770940 CDH1
ILMN_2412475 PRR5

Gene name
E-cadherin

ILMN_1791826 RAB25

proline rich 5
member RAS
oncogene family

ILMN_1782389 LAD1

ladinin 1

ILMN_2143685 CLDN7

claudin 7
transmembrane
protein 30B
epithelial cell
adhesion
molecule

ILMN_1752935 TMEM30B
ILMN_2160210 EPCAM
C10orf116
ILMN_1680110 (ADIRF)
ILMN_1752932 MPZL2
ILMN_1796461 PRSS8
ILMN_1655261 ERP27
ILMN_1699887 ST14
ILMN_1710644 MARVELD3
ILMN_1780255 KLK6
ILMN_1664265 EPHA1
C19orf46
ILMN_1801697 (SYNE4)
ILMN_1685709 TMEM125
ILMN_1746801 CGN

ILMN_1688154 MST1R

adipogenesis
regulatory factor
myelin protein
zero-like 2
protease, serine,
8
endoplasmic
reticulum protein
27
suppression of
tumorigenicity 14
MARVEL domain
containing 3
kallikrein-related
peptidase 6
EPH receptor A1
spectrin repeat
containing,
nuclear envelope
family member 4
transmembrane
protein 125
cingulin
macrophage
stimulating 1
receptor (c-metrelated tyrosine

Function
adhesion, epithelial marker
tumor supressor gene,
component of mTORC2
signalling
membrane trafficking,
member of the RAS family
anchorin filament, epithelial
marker
tight junction, epithelial
marker
phospholipid translocator
adhesion molecule,
epithelial marker
function unknown,
overexpressed in
cancers/platin resistance
cell adhesion/epithelial
marker
membrane-anchored
serine proteases/epithelial
development
endoplasmic reticulum
protein
epithelial-derived, integral
membrane serine protease
(HGF family)
tight junction
proliferation/epithelial
marker
angiogenesis/invasion
involved in changes in
cellular organization
transmembrane protein,
function unknown
tight junction

cell migration

Mean
Expression
(R/S)1,2
59.95
58.17
33.86
33.72
27.42
25.59
24.24
23.40
21.60
21.46
18.81
12.61
11.71
11.36
10.11

9.93
9.73
8.97

7.55
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ILMN_1751346 ERBB3
ILMN_1769201 ELF3
ILMN_2132599 ANKRD22

ILMN_2064150 PRRG2
ILMN_1723092 CRB3
SERINC2
ILMN_2111932 (TDE2)

kinase)
v-erb-b2 avian
erythroblastic
leukemia viral
oncogene
homolog 3
E74-like factor 3
ankyrin repeat
domain 22
proline rich Gla
(Gcarboxyglutamic
acid) 2
crumbs family
member 3

ILMN_2050790 C11orf52

serine
incorporator 2
grainyhead-like 2
(Drosophila)
chromosome 1
open reading
frame 106
keratinocyte
differentiation
factor 1
growth factor
receptor-bound
protein 7
StAR-related lipid
transfer (START)
domain containing
10
v-erb-b2 avian
erythroblastic
leukemia viral
oncogene
homolog 2
immunoglobulinlike domain
containing
receptor 1
chromosome 11
open reading
frame 52

SPINT1
ILMN_1724946 (HAI1)

serine peptidase
inhibitor type 1

ILMN_2060145 GRHL2
ILMN_1713952 C1orf106
C1orf172
ILMN_1676322 (KDF1)
ILMN_2405254 GRB7

ILMN_1717052 STARD10

ILMN_2352131 ERBB2

ILMN_2043079 ILDR1

membrane protein from
EGF receptor family oncogenic
epithelial-specific
transcription factor,
epithelial marker

7.53
7.44

epithelial marker

7.01

Hippo tumor suppressor
pathway

6.85

tight junction
byossinthesis of membrane
lipids, overexpressed in
lung cancer
regulates ERBB3, involved
in EMT

6.78

function unknown

5.67

proliferation/differentiation

5.61

cell migration

5.49

phospholipid transfer
protein

4.97

EGF receptor family oncogenic/cell proliferation

4.40

involved in cancer
development/progression

4.36

function unknown
regulates membrane
anchored serine proteases
(HGF family)

6.23
6.13

4.24
3.94
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ILMN_1790778 PNMA2

tandem C2
domains, nuclear
contactin
associated protein
1
transient receptor
potential cation
channel,
subfamily V,
member 2
paraneoplastic Ma
antigen 2

ILMN_2058251 VIM

vimentin

ILMN_1734596 TC2N
ILMN_1692398 CNTNAP1

ILMN_2049536 TRPV2

involved in vesicular
traffecking

3.87

involved in Rho signalling

0.25

cell migration/invasion

0.16

paraneoplastic antigen
intermediate
filament/cytoskeleton,
mesenchymal marker

0.13
0.05

Table 4. Probe sets with expression that correlated with response to all three
drugs.
1

Fold change in mean gene expression for resistant (R) / sensitive (S) cell lines.
P <0.015 for all values.

2

At the protein level, E-cadherin and β-catenin were consistently expressed at higher
levels in the resistant lines, and DNA-dependent protein kinase catalytic subunit and
thymidylate synthase were consistently overexpressed in the sensitive lines as seen in
Table 5.
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Mean
expression
Sensitivity
Protein
(R/S)
P
FDR = 0.1
E-cadherin
6.65
8.90E-07
β-catenin
4.27
5.29E-05
FDR = 0.2
ATM
0.44
0.0041
TAZ
0.84
0.0043
Universal
FDR = 0.3
Thymidylate synthase 0.62
0.0088
DNA-PKcs
0.54
0.0104
BCl2
0.62
0.0163
MCAM
0.80
0.0179
FDR = 0.2
E-cadherin
3.78
0.0001
β-catenin
2.46
0.0010
FDR = 0.3
Thymidylate synthase 0.68
0.0041
GSK461364
Rab25
1.23
0.0042
P70s6k
1.35
0.0045
MACC1
1.62
0.0064
FDR = 0.1
E-cadherin
3.40
0.0008
BI2536
FDR = 0.2
DNA-PKcs
0.61
0.0040
Table 5. Proteins with expression that correlated with drug sensitivity
R, resistant. S, sensitive. FDR, false discovery rate. PKcs, protein kinase catalytic
subunit.
As an exploratory analysis, we tested probe sets with at least a 2-fold difference
in mean gene expression between sensitive and resistant lines and a corresponding P
value of less than 0.05 for this difference. We performed pathway analysis of lines with
genes whose expression correlated with sensitivity to the universal lines. Tight-junction,
ErbB, and Rho signaling pathways were significantly altered in multiple gene sets
(Table 6).
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Universal
FDR
< 0.2

Ingenuity canonical
pathways
Tight junction
signaling
RhoA signaling
Signaling by Rho
family GTPases
RhoGDI signaling
IL-15 production
Production of nitric
oxide and reactive
oxygen species in
macrophages
Leukocyte
extravasation
signaling
Diphthamide
biosynthesis
Epithelial adherens
junction signaling
Actin nucleation by
ARP-WASP
complex
Acute phase response
signaling
Granulocyte adhesion
and diapedesis
STAT3 Pathway
Molecular
Mechanisms of
Cancer
SAPK/JNK Signaling
PPAR Signaling

P

Genes
F11R, JAM3, CGN, ARHGEF2, CLDN7,
3.5E-05 TNFRSF11B
EPHA1, RTKN, BAIAP2, ARHGAP8/PRR50.001 ARHGAP8
0.002 MAP3K12, CDH1, RHOQ, BAIAP2, ARHGEF2
CDH1, RHOQ, ARHGEF2, ARHGAP8/PRR50.004 ARHGAP8
0.004 PTK6, MST1R

0.004 MAP3K12,PTPN6,RHOQ,TNFRSF11B
F11R,JAM3,CLDN7,ARHGAP8/PRR50.006 ARHGAP8
0.011 DPH5
0.017 EPN3,CDH1,BAIAP2
0.018 RHOQ,BAIAP2
0.025 CRABP2,TAB,TNFRSF11B
0.028 JAM3,CLDN7,TNFRSF11B
0.030 MAP3K12,PTPN6
0.047 CDH1,RHOQ,ARHGEF2,TAB
0.048 MAP3K12,TAB
0.048 TAB,TNFRSF11B

Table 6. Pathway analysis of genes that correlated with Plk1 inhibitor sensitivity
in universal lines. Pathway analysis was performed using IPA from
www.ingenuity.com.
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Based on the differential expression of E-cadherin at mRNA and protein level
(Fig. 20a-b) and several genes involved in EMT as well as our observations that NSCLC
cells with a mesenchymal morphology were more sensitive to Plk1 inhibition than
epithelial cells, we hypothesized that mesenchymal NSCLC cells are more sensitive to
Plk1 inhibition. We applied a 76-gene EMT signature score developed by our
department and the bioinformatics department and which had been validated in multiple
datasets to distinguish sensitive and resistant cell lines (80). EMT scores correlated
significantly with sensitivity to Plk1 inhibition in cell lines sensitive to any one of the
three drugs and particularly in universal lines (Fig. 20c). Cell lines with higher EMT
scores (mesenchymal) were more sensitive to Plk1 inhibitors. Protein expression as
seen by Western blot also confirmed these correlations in the cell lines (Figure 20d).
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Figure 20. Mesenchymal phenotype correlates with sensitivity to Plk1 inhibition
while epithelial phenotype correlates with resistance. E-cadherin gene and protein
expression is significantly correlated with resistance to Plk1 inhibition. Cell lines with
higher EMT scores are also more sensitive to Plk1 inhibition. Expression boxplots were
created with the help of the Bioinformatics department: Drs. Suk Young Yoo, Pan Tong,
Jing Wang.
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As Plk1 inhibitor sensitivity correlated significantly to E-cadherin expression, we
examined the effect of knocking down E-cadherin on volasertib sensitivity.
Manipulation of E-cadherin alone was not sufficient to change the biological effects of
Plk1 inhibition (Fig. 20).

Figure 21. E-cadherin knockdown did not sensitize resistant NSCLC cell lines to
Plk1 inhibition. E-cadherin knock down does not affect NSCLC cell lines’ sensitivity to
PLK1 inhibition. Two epithelial NSCLC cell lines were transfected with siRNA to Ecadherin and then incubated with volasertib 48 h later. The knock down of E-cadherin
did not affect cell cycle (left panel), cell number as measured by MTT (right panel) or
apoptosis as measured by TUNEL (bottom panel). *, P < 0.05 compared to control or as
indicated.
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Induction of epithelial or mesenchymal phenotype affects sensitivity to Plk
inhibition in NSCLC cell lines
To determine if the correlation between EMT scores and drug sensitivity was
biologically significant, we manipulated NSCLC cells and found that Plk1 inhibition led
primarily to apoptosis in mesenchymal cells and cell cycle arrest in epithelial cells. We
transfected NSCLC cell lines with miR-200b and miR-200ab, which have been shown to
induce an epithelial protein expression pattern and phenotype (93). In the H1299 and
H157 cell lines, miR-200b or miR-200ab, respectively, resulted in an increased
expression of E-cadherin and a decreased expression of vimentin. Concurring with the
finding that the epithelial NSCLC lines are more resistant, the induction of an epithelial
phenotype increased the cell lines’ resistance to volasertib, with IC70 values increasing
from 374 nM to >1200 nM in H157 cells and from 321 nM to >1200 nM in H1299 cells
(Fig. 21a). However, the quantity of TUNEL-positive cells did not significantly change
between the uninduced cells and induced cells treated with volasertib. The induction of
a mesenchymal phenotype using ZEB1 overexpression (Fig. 21b) increased the cell
line’s sensitivity to volasertib, with IC70 values decreasing from >1200 nM to 130 nM.
The quantity of TUNEL-positive cells did not significantly change between the control
and ZEB1 cells after treatment with volasertib. TGF-β (Fig. 21c) induced a
mesenchymal phenotype and led to an increase in sensitivity to volasertib, with cell
viability decreasing by over 40%, although the IC70 values could not be detected.
Additionally, TGF- β treated cells underwent significantly more (p < 0.05) apoptosis in
terms of TUNEL stained cells compared to the parental cells.
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Figure 22. Induction of EMT sensitizes NSCLC cell lines to Plk1 inhibition
whereas MET makes cell lines more resistant. Mesenchymal cells are more sensitive
to PLK1 inhibition than epithelial cells using isogenic human NSCLC models. (A)
Forced expression of miR-200 led to increased E-cadherin expression and decreased
vimentin expression as determined by Western blotting and to resistance to volasertib
as measured by MTT assay. Induction of a mesenchymal phenotype using ZEB1
expression (B) or 5 ng/mL TGF-β (C) led to volasertib sensitivity and increased
volasertib-induced apoptosis. *, P < 0.05 compared to control or as indicated.
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Chapter 4: Discussion
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Large scale screen of NSCLC cell lines to Plk1 inhibitors
Previous studies have shown Plk1 inhibitors to have broad antitumor activity in
diverse set of cancer cell lines (46, 58, 61, 94, 95) and mouse xenografts (49, 96). The
GDSC (34) and CCLE (33) databases demonstrated that NSCLC cell lines responded
to Plk1 inhibitors (Figure 6). However, it had not been shown in a large panel of NSCLC
cell lines. In our study, we screened over 50 NSCLC cell lines with BI2536, volasertib,
and GSK461364 by MTT and CellTiter-Glo. We observed that Plk1 inhibition led to
decreased viability in all cell lines, but was substantially different in the sensitive cell
lines compared to the resistant cell lines (Figure 6). We differentiated sensitive cell lines
and resistant cell lines based on the inhibition of 70% of cell growth (IC70) being
reached prior to the Cmax dose. After screening all the cell lines with the three Plk1
inhibitors, we found that a smaller subset of cell lines were either sensitive to all three
inhibitors or resistant to all three inhibitors. This agrees with previous clinical studies
that have shown low response rates to Plk1 inhibition in solid tumors (35, 46, 58, 61).
We then proceeded to analyze correlations of Plk1 inhibitor sensitivity and potential
candidate biomarkers from literature.
Plk1 inhibitors have been approved for use in acute myeloid leukemia (AML) (58,
95). One of the hallmarks of AML is that it has a high mitotic rate (97), meaning it has a
short doubling time. Volasertib has been shown to be highly effective as single agent in
AML (58). We studied if cell doubling time plays a role sensitivity because Plk1 affects
the cell cycle, and cells that divide faster will go through the cell cycle more times than
slower growing cells during the assays. Theoretically, the cells with shorter doubling
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times would therefore be in G2 more frequently, causing them to be more vulnerable to
Plk1 inhibition. This pattern is observed in regards to chemotherapy drugs targeting the
S phase of the cell cycle, as seen by methotrexate (98).Based on the doubling time of 9
(5 resistant, 4 sensitive) NSCLC cell lines, it appears doubling time does not correlate
with sensitivity to Plk1 inhibition. This may have been due to the low absolute number of
NSCLC cell lines used in the analysis.
Previous studies had implicated TP53 and KRAS mutations as predictive
biomarkers of Plk1 inhibition sensitivity. In cancer cells with p53 mutations or low
expression of the protein, depleting Plk1 led to apoptosis following cell cycle arrest and
spindle checkpoint activation (31, 53, 60). Additionally, knockdown of Plk1 preferentially
reduced the survival of p53 deficient, oncogenic transformed cells and tumor growth
(54). In our study, we tested correlation of TP53 mutational status with Plk1 inhibitor
sensitivity, but found no significant correlation was found. This agrees with another
study in which no significant different cytotoxic response between cancer cells with and
without functional p53 was observed in colon, breast, lung, and cervical cancer cell lines
after Plk1 depletion (99).
It has been suggested that KRAS mutant cells are sensitive to Plk1 inhibition,
and it has been observed that KRAS G13D mutant colorectal cancer cell lines,
increased cell death was observed after Plk1 depletion and inhibition (52). Due to the
number of cell lines with only KRAS mutations being low, we put the NRAS and KRAS
mutant cell lines in one group, the RAS mutant lines. The RAS mutant cell lines
correlated with sensitivity for both BI2536 and volasertib (Table 3). To further
characterize KRAS mutants, we applied an established KRAS dependency signature to
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KRAS mutant NSCLC cell lines (64). KRAS-dependent NSCLC cell lines, defined as
those that undergo apoptosis when KRAS is knocked down, exhibit classical epithelial
morphology, whereas KRAS-independent cells display a mesenchymal phenotype (64).
In unsupervised analysis, KRAS-independent cell lines clustered in the sensitive group
for GSK461364 but not for the other 3 groups (Figure 17). Our data suggests that the
response of KRAS mutant cell lines may depend on the inhibitors being used as they
have different pharmacological properties. Additionally, the grouping the NRAS and
KRAS mutant lines may have affected the correlations as they have different biological
properties.
There have not been studies which examine correlation of basal gene and
protein expression to a large panel of cell lines to Plk1 inhibition. As mentioned above,
potential candidate biomarkers were not significantly correlated to response to Plk1
inhibition. To determine why NSCLC cell lines had diverse sensitivities to Plk1 inhibition,
we examined the relationship between drug sensitivity and baseline gene and protein
expression in four groups of cell lines: BI2536-sensitive/resistant, volasertibsensitive/resistant, GSK461364-sensitive/resistant, and the universal cell lines. We
found that the expression levels of several genes and proteins correlated with drug
sensitivity (Table 4,5). E-cadherin and β-catenin were consistently expressed at higher
levels in the resistant lines, while DNA-dependent protein kinase catalytic subunit (DNAPKcs) and thymidylate synthase were consistently overexpressed in the sensitive lines.
The correlation of high E-cadherin expression with resistance to Plk1 inhibition was true
for all three inhibitors, as well as the universal cell lines (Figure 20). The correlation with
E-cadherin had not been previously reported. One link which has been established was
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in the KRAS dependent cell lines which demonstrated less sensitivity to Plk1 depletion
and inhibition compared to KRAS independent colon cancer cell lines. These KRAS
dependent cells exhibited classical epithelial morphology (52, 64). Additionally, DNAPKcs synthase has been reported to associate with Plk1 to ensure proper chromosomal
separation in preparation in anaphase (100). Additionally, β-catenin has been reported
to be a substrate of Plk1 and is associated with signaling involved in chromosomal
segregation, and is involved in cell-cell adhesion and EMT (101, 102).
Biological effects of Plk1 inhibition
Previous studies had used colony formation assays to assay for cell proliferation
effects of Plk1 inhibition in glioma and medulloblastoma cells (99, 103). As another
measure of proliferation, we analyzed colony formation, after pulse treating cells with
volasertib and then continued culturing cells (Figure 10). This assay is distinct from the
MTT as we are not exposing the drug to the cells for a prolonged period. Both total well
area and average colony area decreased significantly in the sensitive cell lines
compared to the resistant cell lines, indicating a greater decrease in proliferation in the
sensitive cell lines. The result mirrored the results from the MTT assays, leading us to
believe that the sensitive cells undergo an irreversible inhibition of proliferation
compared to the resistant cells. The results agreed with previous findings in which
diverse sensitivities were observed through the colony growth after Plk1 inhibitor
treatment (94, 103).
We observed that some of the dose response curves increased upward at higher
concentrations of the drug, representing increased cell number (Figure 6). This has also
been previously by Raab, et al. at which they also saw increased cell number at very
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high doses in HeLa cells (104). This may be resulting from the off-target effects of the
inhibitors, which also target tumor suppressors Plk2 and 3 (30). A large scale
proteomics screen done by the same group identified DAPK as a target which is
targeted by Plk1 inhibition and allows for survival of cells with genetic aberrations (104).
Thus, it is possible that in this study that the drugs are inhibiting tumor suppressors
such as DAPK at high concentrations.
To determine whether the inhibitors were truly inhibiting Plk1 in cell lines, we
looked at the expression of Plk1 targets in NSCLC cell lines. In our work, we
demonstrated that mitotic substrates including Myt1 and indirectly CDK1 were inhibited
by Plk1 inhibitors in both sensitive and resistant cells (Figure 7). Additionally, cyclin B
levels increased following Plk1 inhibitor treatment. This was expected as the
proteasomal degradation of cyclin B is Plk1 dependent. However, there was difference
in the inhibition of phospho-TCTP at Ser46, which is a substrate involved in the spindle
assembly checkpoint and chromosomal separation (42). This may suggest a possible
resistance mechanism, suggesting the distinct biological differences we observe are
occurring at the spindle checkpoint stage. Resistant cells appear to be able to bypass
Plk1 spindle checkpoint signals and continue dividing with aberrant chromosomal
separation. Previous studies have shown that Plk1 inhibition leads to polyploid cells and
multipolar spindles (36, 41, 45, 49, 54, 58, 61). Additionally, assaying for Plk1 activity at
longer timepoints (Figure 9) exhibited similar results. This may additionally suggest that
the target may not be sufficiently inhibited in resistant cell lines at longer time points,
allowing cells to start proliferating again. This is in agreement with what we observed in
the colony formation assays.
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Sensitive cell lines appeared to undergo cell cycle arrest, had increased sub-G0
population, and underwent apoptosis (Figure 11-13). In contrast, resistant cell lines had
an increase in cells with 4N DNA content, increased number of polyploid cells, and
underwent less apoptosis compared to the sensitive cell lines. We are unable to
distinguish if the 4N cells were in G1 or G2 of different cell cycles as we also observe
increased polyploid cells, especially with our resistant cells. Additionally, we observed
an increase in polyploid cells in resistant cells using both through cell cycle analysis and
microscopy. This may be a sign of cells undergoing a mitotic catastrophe. Here, cells
would be able to bypass the spindle assembly checkpoint and divide. Cells which
bypass this checkpoint would now be aneuploid due to improper chromosomal
segregation. These cells are able to go into the next cell cycle and continue dividing
(105). When comparing to Plk1 knockdown in the same cell lines, the same
accumulation of 4N cells was seen after the Plk1 knockdown. There was significantly
more apoptosis in the cells after knockdown compared to inhibition; however, the results
mirrored those from the Plk1 inhibition where we see more apoptosis in that the
sensitive cell lines compared to the resistant cell lines, confirming the effects of the
inhibitors in NSCLC cell lines were mainly Plk1-driven.
One mechanism which may be leading to this resistance is the expression of
ABC transporter proteins involved in multi-drug resistance. Plk1 inhibitor resistance has
been implicated with the expression of ATP Binding Cassette transporter proteins which
are involved in multi-drug resistance mechanisms (46, 90). We evaluated basal gene
expression of ATP-binding cassette (ABC) transporters ABCB1 and ABCG2 with
sensitivity to the three Plk1 inhibitors. No statistically significant correlation was found
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(Figure 19). Although ABC transporter mRNA levels did not correlate, there is evidence
to suggest that these proteins are highly regulated at the translational level (106, 107).
In the case of the dose-dependent response Western blots, we saw substrate
reactivation at high concentrations for GSK461364 (Figure 7). When we examined
protein expression of different ABC transporters, we saw induction of expression of
ABCB1 and ABCC10 (Figure 8). There have been previous reports of ABC transporters
being involved in a possible resistance mechanism for this particular inhibitor (31, 90).
Previous studies had demonstrated that treatment of GSK461364 in ABCB1
overexpressing ovarian cancer cell lines led to the efflux of transporter substrate dyes
(90, 106, 107). Assaying for activity through dye efflux would help us understand if
inhibitors are substrates of these proteins. Additionally, the combination of Plk1
inhibitors and MDR1 inhibitors may lead to sensitization of resistant cells if this is the
major issue.
Plk1 inhibition and EMT
After analyzing gene and protein expression, it was evident that EMT related
proteins are highly correlated with Plk1 inhibitor sensitivity in NSCLC cell lines. Ecadherin expression was highest in the resistant cell lines. In 2013, Byers et al
published an EMT gene signature (80). The signature is based on a set of 76 genes
related to EMT which were validated using gene expression from four platforms in
NSCLC cell lines and tumor samples from the BATTLE study. The signature was able to
predict resistance to EGFR inhibitors and PI3K/Akt inhibitors. We discovered that
NSCLC lines with high EMT scores (more mesenchymal cell lines) are more sensitive to
all three Plk1 inhibitors. In addition, forced induction of an epithelial phenotype resulted

104

in drug resistance, and forced induction of a mesenchymal phenotype increased drug
sensitivity. Recent publications have demonstrated that the miR-200-ZEB1 axis is
crucial in the regulation of the EMT phenotype (93, 108, 109). It was also seen that the
manipulation of EMT related transcription factor ZEB1 and miR-200, which are
repressors and activators of E-cadherin expression respectively, slightly reversed
sensitivity or resistance. However, only knocking down E-cadherin using siRNA did not
change sensitivity to the Plk1 inhibition. Treatment of cells with TGF- β is also known to
induce EMT through the activation of Smad proteins and other EMT-related pathways
(65, 66, 73, 74, 109). Inducing EMT through treatment with TGF- β resulted in a
significant increase in apoptosis in a universal resistant cell line H358.
Tight-junction and Rho signaling pathways are also related to EMT, and these
pathways were enriched, as seen by analyzing the pathways altered in our differential
gene expression (Table 6). Tight junctions are an extremely important component of
the signaling pathways that regulate epithelial proliferation and differentiation (110-112).
Additionally, Rho family GTPases are essential for epithelial cell polarity, tight-junction
assembly, and regulation of the actin cytoskeleton (113). It is also interesting to note
that one of the ways TGF- β facilitates EMT in non Smad related processes is by
regulating Rho GTPases (65).
No previous studies had linked mesenchymal phenotypes to Plk1 inhibitor
sensitivity. However, previous studies had shown that breast cancer and glioblastoma
cell lines were more susceptible to Plk1 inhibition; these cell lines are known to be more
mesenchymal (50, 94). The change in morphology appears to dictate the sensitivity and
resistance, as evidenced by our isogenic models, in which we were able to induce cells
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to become either more epithelial or more mesenchymal. However, this may be a
secondary effect of the alteration of several pathways rather than the primary
mechanism. For example, when we manipulated the expression of E-cadherin through
siRNA, we did not see significant changes in apoptosis. Additionally, ZEB1 and miR-200
primarily affect EMT status through modulation of E-cadherin expression (93). Although
we saw changes in the MTT assays using these models, we did not observe significant
differences in apoptosis after treatment compared to controls. However, TGF- β
induced EMT resulted in cells undergoing significantly more apoptosis compared to the
parental cell lines. TGF- β is known to affect several signaling pathways, not just EMT
related, which may play a role in affecting sensitivity.
Conclusions
As we saw, the NSCLC cell lines demonstrated diverse sensitivities to Plk1
inhibition. Sensitive and resistant cell lines exhibited different biological responses to
Plk1 inhibition. Sensitive NSCLC cell lines undergo significantly more apoptosis
compared to resistant cell lines. Gene and protein expression profiles showed that
expression of specific sets of genes and proteins, especially those related to EMT,
significantly correlate with response to Plk1 inhibitors, which may be used as predictive
biomarkers. Finally, modulation of EMT status in NSCLC cell lines leads to changes in
sensitivity.
The major implications of this study are the potential for clinical benefits. As we
chose the most clinically relevant Plk1 inhibitors, our findings have translational impact.
Most mesenchymal type cancers are resistant to therapies (114, 115). Additionally,
EMT is one of the mechanisms leading to loss of oncogene addiction (116). More
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mesenchymal tumors usually have worse prognosis and represent an unmet need in
terms of today’s cancer therapy. If Plk1 inhibitors are effective in mesenchymal tumors
in vivo, this may provide a possible therapeutic benefit for those patients who may suffer
from this disease. Additionally, it would be interesting to see if the diverse biological
responses we observed were distinguished based on EMT status.
One limitation of our study is the poor correlation of the effects of the two
Boehringer Ingelheim compounds (BI2536 and volasertib) with the effects of
GSK461364. The differences in the drugs’ effects may be attributed to differences in the
drugs’ selectivities (GSK461364 is more selective against Plk1). Similar inconsistencies
have been reported in two large-scale pharmacogenomic studies, where genomic data
were well correlated between the studies, but responses of the drugs highly discordant
(117). Additionally, we noted that in some cell lines, higher drug concentrations had less
of an effect on cell viability than intermediate concentrations (Figure 6). Additionally, in
our cell screening assays, the MTT and CellTiter-Glo assays do not distinguish if cells
are in cell cycle arrest or are undergoing apoptosis (118). These assays may not
completely reflect the cell growth of the cells following Plk1 inhbition.
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Future Directions
Although we clearly demonstrated that mesenchymal NSCLC cell lines were
more sensitive to Plk1 inhibition, future studies should focus on the mechanisms that
lead to Plk1-inhibitor induced apoptosis in mesenchymal cells. To study this
mechanism, we could use unbiased methods to identify potential mechanisms which
are contributing to the link between EMT and the Plk1 inhibitor-induced apoptosis. As
we have been able to establish isogenic models in which we are able to reverse
sensitivity and resistance, we could run gene expression arrays and RPPA pre and post
treatment to determine which signaling pathways are differentially regulated in the
models. In this case, we are not focused to a singular pathway to study, but rather
several different pathways which may contribute to the effects we are seeing. As we
saw, induction of EMT through TGF-β sensitized the cells and MET through miR-200
made cells more resistant. We would be able to use these models and either use Plk1
inhibitors or siRNA against Plk1 to see which pathways are differentially regulated.
Additionally, we saw that tight junction signaling was enriched in our resistant cell
lines based on our gene expression data. This may be an area of study in which we
could manipulate the genes regulating this pathway in resistant cell lines to see if
alteration may lead to a change in sensitivity. As we know, proteins related to tight
junction signaling are related to epithelial cell polarity and adhesions, especially in the
case of claudins and occluding, which were differentially expressed. The Rho-family of
GTPases also is implicated in the regulation of these cell-cell junctions, and may be
another area of study. Another major target we could study, in terms of mechanism is
role of β-catenin. The expression of β-catenin, both at the mRNA and protein level
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highly correlated with resistance. As has been reported, it is related to tight junction
signaling, cell polarity, and cell-cell junctions. Additionally, it has been reported that β
catenin and Wnt signaling play important regulatory roles in the nucleus where it is
important in centrosomal separation (102), interacting with NEK2, which is a substrate
of Plk1 (101).
Plk1 may synergize with DNA damaging agents such as chemotherapy and
radiotherapy to kill cancer cells (95, 119). In this regard, in the differential gene
expression patterns, sensitive cells lines had altered DNA damage-related proteins
compared to resistant lines. This may open up new directions to study in terms of
combinations. We may also be able to combine DNA damaging agents such as cisplatin
or gemcitabine with Plk1 inhibitors. If the resistant cell lines are able to continue cycling
and go into subsequent cell cycles with aneuploidy, we may be able to use drugs
targeting the S phase to target cells which are resistant to Plk1 inhibition.
We observed that some EGFR tyrosine kinase inhibitor acquired resistant cell
lines became more mesenchymal and more sensitive to Plk1 inhibition. Three different
cell lines had been tested, and of these, two became more mesenchymal to acquire
resistance to EGFR tyrosine kinase inhibitor erlotinib (preliminary data, not shown).
HCC827 and HCC4006 parental cell lines were among those which were universally
resistant in our screen of the Plk1 inhibitors. In these resistant clones, it has been seen
that Axl kinase expression has been elevated. This has been reported as a potential
mechanism leading to mitotic kinase inhibitor vulnerability in conjunction with Axl
inhibitors by Dr. Jeff Settleman’s group (120). Additionally, the isogenic model in which
TGF-β was used to change the morphology of H358 cell line into a mesenchymal cell
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line was shown to have significant increase in apoptosis in our study. It has been
reported that TGF-β induced H358 is also resistant to erlotinib and had increased Axl
(120). This may be another potential area of study in which we can determine if
acquired resistance to erlotinib through EMT and increased Axl may contribute to Plk1
inhibitor sensitivity through the EGFR pathway. There also may be the potential for
combination studies with erlotinib to sensitize cell lines which are resistant to erlotinib
with a Plk1 inhibitor such as volasertib.
Our in vitro studies using Plk1 inhibitors have shown a strong correlation with
EMT scores and E-cadherin alone. E-cadherin expression may present a simple
biomarker for Plk1 inhibitor response. To test this hypothesis, the next logical step
would be to move to in vivo models, using cell line xenografts with diverse EMT status.
However, more telling in terms of translational relevance, it would be interesting to study
the response in patient derived xenograft (PDX) or genetically engineered mouse
models. The study of Plk1 inhibitor response in PDX models would be a stronger tool as
these models are closer to human tumors. We may be able to establish PDX models to
be able to treat tumors in mice and determine the EMT status of these tumors to see if
the relationship of EMT status and Plk1 inhibitor sensitivity holds in this setting.
If the results from such in vivo studies would yield promising results, we may be
able to test our conclusions in a clinical trial with FDA approved Plk1 inhibitors
(volasertib). E-cadherin expression may serve as a simple biomarker to predict
response to Plk1 inhibitors in NSCLC patients. Biopsies taken from patients may be
analyzed for EMT biomarkers, such as E-cadherin, and patients can be randomized into
different groups. In the clinical setting, mesenchymal tumors are typically more resistant
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to standard therapeutic regimens. If our hypothesis holds, then Plk1 inhibitors will be a
choice for patient treatment modalities.
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Appendix
H358 Ungated Cell Cycle

Calu-6 Ungated Cell Cycle

Control

24h volasertib
(50nM)

48h volasertib
(50 nM)

122

H322 si Plk1 Ungated Cell Cycle

Calu-6 siPlk1 Ungated Cell Cycle

Control

24h si Plk1

48h si Plk1
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H358

H358
TGF-B

H358
+ Vol

H358
TGF-B
+ Vol

Cell Cycle for H358 parental cells (top panel) and H358 TGF-B cells (bottom panel)
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